AMBU APPOINTS NEW CHIEF MARKETING OFFICER
Jesper Johnsen Steen has been appointed as Ambu’s new Chief Marketing Officer, effective 1 May 2025.

Today, Ambu A/S announces the appointment of Jesper Johnsen Steen as the company’s new Chief Marketing Officer and member of the Executive Leadership Team, effective 1 May 2025.
"I am confident that Jesper, with his strong commercial expertise and leadership, will be a driving force in shaping Ambu’s innovative solutions portfolio. His ability to understand market dynamics and anticipate customer needs will be instrumental in ensuring that our solutions not only deliver customer value through a strong value proposition and clear differentiation; but also resonate deeply with the challenges and expectations of our customers.
With a customer-centric approach, Jesper and his team will advance Ambu’s reputation even further in the healthcare industry as a trusted partner, committed to serving the needs of our customers and delivering impactful and transformative solutions."
BRITT MEELBY JENSEN
Chief Executive Officer, Ambu
STRONG COMMERCIAL PROFILE WITHIN MEDTECH
Jesper Johnsen Steen is an accomplished leader with 20 years of experience in the MedTech industry. He has held influential leadership positions in several different set-ups and countries. Most recently, he served as Senior Vice President for Coloplast’s Wound & Skin Care business.
Throughout his extensive career, Jesper has demonstrated strong commercial and international expertise. He brings in-depth knowledge to Ambu across diverse fields, including marketing, sales, commercial excellence, P&L management, product and portfolio management, strategy planning and transformation. Additionally, he has operated in markets of varying maturity, from emerging to fully developed, across North America, Europe, Asia, Australia, Middle East and Africa. This diverse experience will be invaluable in ensuring that Ambu remains competitive and innovative within the ever-evolving healthcare industry.
"I am honoured and humbled to join Ambu, which stands out as an inspiring company with significant opportunities, great customer solutions and a set of values that align closely with my own. I am excited to contribute to its continued success."
JESPER JOHNSEN STEEN
Chief Marketing Officer, Ambu
Keywords
Contacts
Tine Bjørn SchmidtDirector of Corporate Communications
Tel:+45 2264 0697tisc@ambu.comAnders HjortHead of Investor Relations
Tel:+45 2892 8881anhj@ambu.comImages

Documents
About Ambu
Since 1937, Ambu has been rethinking solutions, together with healthcare professionals, to save lives and improve patient care. From development and manufacturing to distribution and sale, we oversee the entire product lifecycle for our healthcare solutions across the fields of single-use endoscopy, anaesthesia and patient monitoring. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our high-quality solutions.
Headquartered in Denmark, Ambu employs around 5,000 people in North America, Europe, Latin America and Asia Pacific.
For more information, please visit Ambu.com.
Subscribe to releases from Ambu A/S
Subscribe to all the latest releases from Ambu A/S by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Ambu A/S
AMBU EXPANDS CE MARK FOR EXISTING UROLOGY SOLUTION, ENABLES NEW TYPE OF PROCEDURE19.2.2025 10:41:31 CET | Press release
With the CE mark expansion for Ambu® aScope™ 5 Cysto HD, urologists will now be able to use the medical technology as a single-use flexible cysto-nephroscopy solution, reflecting Ambu’s commitment to addressing a growing range of urology needs for patients and healthcare professionals.
AMBU LAUNCHES NEW VIDEO LARYNGOSCOPY SOLUTION6.1.2025 16:05:55 CET | Press release
With the launch of the Ambu® SureSight™ Connect solution, Ambu offers clinicians the only airway visualisation and pulmonology offering that features a one-lung ventilation solution and includes all the devices recommended for intubation and airway assessment.
AMBU LAUNCHES HD CYSTOSCOPY SOLUTION IN THE U.S.17.10.2024 16:46:40 CEST | Press release
Following the FDA clearance for the Ambu® aScope™ 5 Cysto HD solution, Ambu introduces its HD cystoscope to urologists in the USA, expanding the urology offering and meeting advanced needs for cystoscopy procedures requiring superior image quality.
AMBU OBTAINS CE MARK FOR NEW GENERATION DUODENOSCOPY SOLUTION8.8.2024 13:00:00 CEST | Press release
Having obtained both CE mark and FDA clearance, Ambu continues its controlled market release phase, focused on evaluation in key hospitals in the USA and Europe.
AMBU OBTAINS FDA CLEARANCE FOR NEW URETEROSCOPY ENDOSCOPY SOLUTION26.6.2024 14:00:00 CEST | Press release
The new clearance marks Ambu’s rapidly growing presence in urology, advancing the company’s urology portfolio in the U.S. market.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom